期刊文献+

肺癌的免疫治疗进展 被引量:8

Advances in Immunotherapy for Lung Cancer
在线阅读 下载PDF
导出
摘要 肺癌已占癌症死亡率的首位,需要新的治疗方法十分迫切。免疫治疗代表了一种低毒,高特异性的新肺癌已占癌症死亡率的首位,需要新的治疗方法十分迫切。免疫治疗代表了一种低毒,高特异性的新治疗方法,但是因为肺癌的免疫原性很弱且存在免疫逃逸,使施行免疫治疗十分困难。本文综述了肺癌的非特异性免疫治疗、细胞免疫治疗、瘤苗和基因治疗现状及最新进展。 Lung cancer is the leading cause of cancer death in China. New approaches of treating lung cancer are urgently needed. With low toxicity and high specificity, immunotherapy is a new treatment. But the implementation is always a challenge because of the immunogenicity and immune escape of lung cancer. In this article we reviewed the current status of development and recent progress in non-specific immune stimulation, cellular immunotherapy, therapeutic cancer vaccines and gene therapy for lung cancer.
作者 尤健 王长利
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2008年第17期1015-1017,共3页 Chinese Journal of Clinical Oncology
关键词 肺癌 免疫治疗 瘤苗 基因治疗 Lung cancer Immunotherapy Tumor vaccine Genetherapy
  • 相关文献

参考文献13

  • 1杨景伟,魏煜程,沈毅.肺癌免疫逃逸研究进展[J].青岛大学医学院学报,2007,43(3):278-279. 被引量:4
  • 2卢晓婷,刘俊田.CD_4+CD_(25)+调节性T细胞在肿瘤免疫及化疗方面的研究进展[J].中国肿瘤临床,2008,35(11):656-658. 被引量:29
  • 3Ratto GB, Zino P, Mirabelli S, et al. A randomized trial of adoptive immunotherapy with tumor--infiltrating lyrnphocytes and interlettkin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung carcinoma[J]. Cancer, 1996, 78(2): 244--251.
  • 4Salgia R, Lynch T, Skarin A, et al. Vaccination with irradiated autologous tumor ceils engineered to secrete granulocyt---emacrophage colony stimulating factor augments anti--tumor immunity in patients with metastatic non--small cell lung carcinoma [J].J Clin Oncol, 2003, 21(4): 624---630.
  • 5NemunaitisJ, Jahan T, Ross H, et al. Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non--small--cell lung cancer[J]. Cancer Gene Ther, 2006, 13(6): 555--562.
  • 6Edmund K. Waller. The Role of Sargramostim (rhGM--CSF) as Immunotherapy[J]. Oncologist, 2007, 12(supp12): 22-26.
  • 7Dominik R/ittinger, The Natasja K van den Engel, Hauke Winter, et al. Adjuvant therapeutic vaccination in patients with non--small cell lung cancer made lymphopenic and reconstituted with autologous PBMG: first clinical experience and evidence of an immune response[J].Journal of Translational Medicine, 2007, 5: 43-57.
  • 8Palmer M, Parker J, Modl S, et al. Phase I study of the BLP25 (MUC1 Peptide) liposornale vaccine for active specific immunotherapy in stage ⅢB/Ⅳ non-small--cell lung cancer[J]. Clin Lung Cancer, 2001, 3(1): 49--57.
  • 9Grant SC, Kris MG, Houghton AN, et al. Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus bacillus calmette-guerin[J]. Clin Cancer Res, 1999, 5(6): 1319-1323.
  • 10施安国.抗癌药物治疗新进展—反义治疗[J].中国肿瘤临床,2003,30(9):674-677. 被引量:2

二级参考文献63

  • 1刘莉,姚军霞,丁乾,黄士昂.非霍奇金淋巴瘤患者外周血CD4^+CD25^(high)调节性T细胞研究[J].中国实验血液学杂志,2006,14(1):119-122. 被引量:31
  • 2[1]Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer[J]. N Engl J Med, 2002, 346:92~98
  • 3[2]Fontanini G, Vignati S, Boldrini L, et al. Vascular endothelail growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma [J]. Clin Cancer Res, 1997, 3:861~865
  • 4[3]Volm M, Koomagi R, Mattem J, et al. Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer[J]. Int J Cancer, 1997, 74:64~68
  • 5[4]Ohta Y, Endo Y, Tanaka M, et al. Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer[J]. Clin Cancer Res, 1996, 2:1411~1416
  • 6[5]Fontanini G, Faviana P, Lucchi M, et al. A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma[J]. Br J Cancer, 2002, 86:558~563
  • 7[6]Offersen BV, Pfeiffer P, Hamilton-Dutoit S, et al. Patterns of angiogenesis in nonsmall-cell lung carcinoma[J]. Cancer, 2001,91:1500~1509
  • 8[7]Koukourakis MI, Giatromanolaki A, Thorpe PE, et al. Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer[J]. Cancer Res, 2000, 60:3088~3095
  • 9[8]Aikawa H, Takahashi H, Fujimura S, et al. Immunohistochemical study on tumor angiogenic factors in non-small cell lung cancer[J]. Anticancer Res, 1999, 19:4305~4309
  • 10[9]Imoto H, Osaki T, Taga S, et al. Vascular endothelial growth factor expression in nonsmall-cell lung carcinoma: prognostic significance in squamous cell carcinoma [J]. J Thorac Cardiovasc Surg, 1998, 115:1007~1014

共引文献32

同被引文献81

引证文献8

二级引证文献48

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部